Literature DB >> 9438390

Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.

P Y d'Avis1, S C Robertson, A N Meyer, W M Bardwell, M K Webster, D J Donoghue.   

Abstract

Thanatophoric dysplasia type I (TDI) is a neonatal lethal skeletal dysplasia caused by several mutations in the extracellular domain of fibroblast growth factor receptor 3. These mutations occur either in the Ig2-Ig3 linker domain or in the extracellular juxtamembrane domain, and all involve mutation of the wild-type residue to Cys. In all cases, the presence of the mutant Cys residue allows the receptor to dimerize abnormally, resulting in ligand-independent activation. This is also manifested by increased biological signaling, increased tyrosine phosphorylation, and in vitro kinase activity associated with dimeric receptors. These results suggest that TDI is caused by Cys-mediated intermolecular disulfide bonding, leading to constitutive receptor activation as a result of these mutations. Mutations causing TDI are discussed with respect to activating mutations in other receptors that are implicated in human disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9438390

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  29 in total

1.  Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase.

Authors:  C A Bell; J A Tynan; K C Hart; A N Meyer; S C Robertson; D J Donoghue
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

Review 2.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

Review 3.  Targeting Signaling Transduction Pathways in Bladder Cancer.

Authors:  Phillip H Abbosh; David J McConkey; Elizabeth R Plimack
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

4.  Typical achondroplasia secondary to a unique insertional variant of FGFR3 with in vitro demonstration of its effect on FGFR3 function.

Authors:  April N Meyer; Peggy Modaff; Clark G Wang; Elizabeth Wohler; Nara L Sobreira; Daniel J Donoghue; Richard M Pauli
Journal:  Am J Med Genet A       Date:  2020-12-02       Impact factor: 2.802

5.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Authors:  M L Lux; B P Rubin; T L Biase; C J Chen; T Maclure; G Demetri; S Xiao; S Singer; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

6.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

Authors:  Heidi Greulich; Bethany Kaplan; Philipp Mertins; Tzu-Hsiu Chen; Kumiko E Tanaka; Cai-Hong Yun; Xiaohong Zhang; Se-Hoon Lee; Jeonghee Cho; Lauren Ambrogio; Rachel Liao; Marcin Imielinski; Shantanu Banerji; Alice H Berger; Michael S Lawrence; Jinghui Zhang; Nam H Pho; Sarah R Walker; Wendy Winckler; Gad Getz; David Frank; William C Hahn; Michael J Eck; D R Mani; Jacob D Jaffe; Steven A Carr; Kwok-Kin Wong; Matthew Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

Review 7.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

8.  A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.

Authors:  Rekha Gyanchandani; Marcus V Ortega Alves; Jeffrey N Myers; Seungwon Kim
Journal:  Mol Cancer Res       Date:  2013-10-03       Impact factor: 5.852

9.  Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Authors:  Jing Qing; Xiangnan Du; Yongmei Chen; Pamela Chan; Hao Li; Ping Wu; Scot Marsters; Scott Stawicki; Janet Tien; Klara Totpal; Sarajane Ross; Susanna Stinson; David Dornan; Dorothy French; Qian-Rena Wang; Jean-Philippe Stephan; Yan Wu; Christian Wiesmann; Avi Ashkenazi
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

10.  Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

Authors:  E di Martino; C G L'Hôte; W Kennedy; D C Tomlinson; M A Knowles
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.